N-benzoyl-N'-formylethylenediamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzoyl-N'-formylethylenediamine
• 英文别名: N-(2-formylaminoethyl)benzamide；N-(2-formamidoethyl)benzamide
• 化学式: C₁₀H₁₂N₂O₂
• 分子量: 192.217
• InChiKey: CJIZKALWLANXHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-benzoyl-N'-formylethylenediamine 在 sodium hydroxide 、 苄基三乙基溴化铵 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以100%的产率得到N-(2-氨基乙基)苯甲酰胺
  参考文献：
  名称：

  Petride, Horia; Costan, Oana; Florea, Cristina, Revue Roumaine de Chimie, 2006, vol. 51, # 4, p. 245 - 253

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-氨基乙基)苯甲酰胺 、 甲酸乙酯 反应 10.0h， 以82%的产率得到N-benzoyl-N'-formylethylenediamine
  参考文献：
  名称：

  Petride, Horia; Costan, Oana; Florea, Cristina, Revue Roumaine de Chimie, 2006, vol. 51, # 4, p. 245 - 253

  摘要：

  DOI：

文献信息

• Tandem oxidation processes for the preparation of nitrogen-containing heteroaromatic and heterocyclic compounds
  作者：Steven A. Raw、Cecilia D. Wilfred、Richard J. K. Taylor

  DOI：10.1039/b315689c

  日期：——

  alpha-hydroxy ketones undergo manganese dioxide-mediated oxidation followed by in situ trapping with aromatic or aliphatic 1,2-diamines to give quinoxalines or dihydropyrazines, respectively, in a one-pot procedure which avoids the need to isolate the highly reactive dicarbonyl intermediates. The scope and limitations of these procedures are outlined and modifications to this procedure are discussed

  α-羟基酮经过二氧化锰介导的氧化，然后通过一锅法分别与芳香族或脂肪族1,2-二胺原位捕获，分别得到喹喔啉或二氢吡嗪，避免了分离高反应性二羰基中间体的需要。概述了这些方法的范围和局限性，并讨论了对该方法的修改，其中在同一反应容器中进行还原，生成哌嗪或氧化生成吡嗪。
• N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
  申请人：——

  公开号：US20040082639A1

  公开（公告）日：2004-04-29

  The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.

  该发明涉及N-取代的三环3-氨基吡唑衍生物，它们可用作血小板源性生长因子受体（PDGF-R）激酶的抑制剂，以及制备该衍生物的方法。本发明还涉及包含本发明化合物的药物组合物，以及治疗肿瘤和其他细胞增殖性疾病的方法。
• Novel isoindole derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US20040053923A1

  公开（公告）日：2004-03-18

  This invention relates to compounds represented by the general formula [I] 1 wherein, R represents an azido group, etc., R 1 and R 2 are the same or different and represent hydrogen atoms, etc., R 3 and R 4 are the same or different and represent hydrogen atoms, etc., X 1 represents an oxygen atom, etc., X 2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及由一般式[I]1表示的化合物，其中，R代表叠氮基等，R1和R2相同或不同，代表氢原子等，R3和R4相同或不同，代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表紧缩芳基基团等，或其药学上可接受的盐，其制备方法以及作为治疗糖尿病的药物、预防糖尿病慢性并发症的预防剂或抗肥胖药物的有效成分，包含该化合物或其药学上可接受的盐。
• N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
  申请人：Ho Yung Chih

  公开号：US20070142305A1

  公开（公告）日：2007-06-21

  The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell. proliferative disorders.

  本发明涉及N-取代的三环3-氨基吡唑衍生物，其可用作血小板源性生长因子受体（PDGF-R）激酶的抑制剂，以及制备该衍生物的方法。本发明进一步涉及包含本发明化合物的制药组合物，并用于治疗肿瘤和其他细胞增殖性疾病的方法。
• NOVEL ISOINDOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1207161A1

  公开（公告）日：2002-05-22

  This invention relates to compounds represented by the general formula [I] wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及通式[I]所代表的化合物 其中，R代表叠氮基等，R1和R2相同或不同且代表氢原子等，R3和R4相同或不同且代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表缩合芳基等、或其药学上可接受的盐、其制备工艺，以及含有该化合物或其药学上可接受的盐作为有效成分的治疗糖尿病的药物、治疗糖尿病慢性并发症的预防药物或防治肥胖症的药物。